Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10

N Raulf1,5, R El-Attar1,5, D Kulms2, D Lecis3, D Delia3, H Walczak4, K Papenfuss4, E Odell1 and M Tavassoli*,1

1Department of Molecular Oncology, King’s College London, Guy’s Hospital Campus, Hodgkin Building, London SE1 1UL, UK; 2Experimental Dermatology, Department of Dermatology, TU-Dresden, Fetscherstrasse 74, 01307 Dresden, Germany; 3Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milano, Italy and 4Centre for Cell Death, Cancer and Inflammation (CCCI) UCL Cancer Institute, 72 Huntley Street, London WC1E 6BT, UK

Background: Current treatment strategies for head and neck cancer are associated with significant morbidity and up to 50% of patients relapse, highlighting the need for more specific and effective therapeutics. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and Smac mimetics (SMs) are promising anticancer agents, but their effect on head and neck squamous cell carcinoma (HNSCC) remains unknown.

Methods: We examined the response of a panel of nine HNSCC cell lines to TRAIL and SMs and investigated the mechanism of cell type-specific response by functional analysis.

Results: Head and neck cancer cell lines revealed a converse response pattern with three cell lines being highly sensitive to Smac-164 (SM) but resistant to TRAIL, whereas the other six were sensitive to TRAIL but resistant to SM. Distinct protein expression and activation patterns were found to be associated with susceptibility of HNSCC cell lines to TRAIL and SM. Tumour necrosis factor-related apoptosis-inducing ligand sensitivity was associated with high caspase-8 and Bid protein levels, and TRAIL-sensitive cell lines were killed via the type II extrinsic apoptotic pathway. Smac mimetic-sensitive cells expressed low levels of caspase-8 and Bid but had high TNF-α expression. Smac mimetic-induced cell death was associated with caspase-10 activation, suggesting that in the absence of caspase-8, caspase-10 mediates response to SM. Cotreatment with TNF-α sensitised the resistant cells to SM, demonstrating a decisive role for TNF-α-driven feedback loop in SM sensitivity.

Conclusions: Tumour necrosis factor-related apoptosis-inducing ligand and SMs effectively kill HNSCC cell lines and therefore represent potential targeted therapeutics for head and neck cancer. Distinct molecular mechanisms determine the sensitivity to each agent, with levels of TNF-α, caspase-8, Bid and caspase-10 providing important predictive biomarkers of response to these agents.

Surgery and radiotherapy alone or in combination with chemotherapy are the common treatment modalities for head and neck cancer. However, they have severe side effects and more than 50% of patients relapse (Suh et al, 2014). This highlights the need for more effective, targeted therapies and for the development of strategies to select patients who could benefit from specific treatment regimens.

In recent years, novel therapeutic agents have emerged that target specific molecules involved in apoptotic pathways. The tumour necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) shows selective cytotoxicity in several types of malignant cell lines (Falschleiner et al., 2009) and recombinant TRAIL is currently used in phase I/II clinical trials for the treatment of patients with advanced tumours (Herbst et al., 2010). Tumour necrosis factor-related apoptosis-inducing ligand induces cell death by binding to its corresponding cell surface receptors TRAIL-R1 or -R2. Upon clustering, the activated receptors recruit several cytosolic proteins to form the death-inducing signalling complex (DISC) (Wang and El-Deiry, 2003). This leads to the activation of the initiator caspase-8 and/or -10 (Juo et al., 1999), which can in turn trigger two different extrinsic apoptotic pathways. In the type I pathway, caspase-8 directly activates the effector caspases (caspase-3, -6 and -7) resulting in the execution of apoptotic cell death, whereas the type II pathway involves caspase-8–dependent cleavage of Bid. Cleaved Bid initiates the permeabilisation of the outer mitochondrial membrane, leading to cytochrome c release, activation of the initiator caspase-9 and the caspase cascade involving caspase-3 (Kryut, 2008; Kantari and Walczak, 2011).

Smac mimetics (SMs) are a class of targeted anticancer drugs that have been developed to mimic functionally the endogenous proapoptotic protein Smac/Diablo (Chen and Huerta, 2009). Smac/ Diablo is a mitochondrial protein that is released into the cytoplasm following permeabilisation of the outer mitochondrial membrane in response to an intrinsic death stimulus (Du et al., 2000; Yang and Yu, 2003). This protein is a natural inhibitor of a family of inhibitor of apoptosis proteins (IAPs) (Du et al., 2000), including cIAP-1, cIAP-2 and XIAP. So far, XIAP has been the only IAP family member for which direct binding to and inhibition of caspases-3, -7 and -9 by proteasomal degradation has been described (Deveraux et al., 1997; Petersen et al., 2007; Varfolomeev et al., 2007). In contrast to this, the precise roles of cIAP-1 and -2 are currently not known. Accumulating evidence suggests that cIAP-1 and -2 are involved in various signal-transduction pathways, including NF-kB activation and TNF-α secretion (Mahoney et al., 2008), leading to the induction of apoptotic (Tenev et al., 2011) or necrotic cell death (McComb et al., 2012). Different types of SMs have been developed as potential anticancer agents with varying modes of action, for example, induction of TNF-α-dependent apoptosis (Petersen et al., 2007) and blocking of IAP activity (Creagh et al., 2004; Bockbrader et al., 2005).

Both TRAIL and SMs have been tested in several cancer models, but very little data are available on their therapeutic potential in HNSCC (Kryut, 2008; Chen and Huerta, 2009; Gasparini et al., 2013). In this study, we have tested the sensitivity of a panel of HNSCC cell lines to TRAIL and Smac-164 (SM) and identified a cell line–specific response. The sensitivity of a cell line to TRAIL or SM was found to be determined by the expression pattern of components of apoptotic signalling pathways and TNF-α levels. Importantly, in HNSCC cell lines with low caspase-8 levels, SM treatment induced caspase-10 activation. These findings identify cell type-specific mechanisms of TRAIL and SM action and provide potential biomarkers for selecting tumours that are likely to benefit from such treatments.

**MATERIALS AND METHODS**

**Cell lines.** The cell lines HSC3 and HSC3M3 are a gift from Dr Kazuya Tominaga, Department of Oral Pathology, Osaka Dental University (Hirakata, Osaka, Japan). The HNS5 cell line was provided by Dr Barry Gusterson, Department of Pathology, University of Glasgow (Glasgow, UK). The HN30 cell line was a gift from Dr Andrew Yeudall, Philips Institute of Oral and Craniofacial Molecular Biology (Richmond, VA, USA). The H357 cell line was a gift from Dr Stephen Prime, Department of Oral and Dental Science, University of Bristol (Bristol, UK). UMSCC74B, UMSCC11B and UMSCC22B were provided by Dr Thomas E Carey, University of Michigan (Ann Arbor, MI, USA). All cell lines except H357 were cultured in DMEM supplemented with 10% FCS, 50 μg/ml streptomycin, 100 μg/ml penicillin and 1 mM sodium pyruvate and incubated at 37 °C and 5% CO2. H357 cells were cultured in DMEM-F12 supplemented with 5% FCS, 4 mM l-glutamine, 69 mM hydrocortisone, 5 μg/ml streptomycin, 5 μg/ml penicillin and 1 mM sodium pyruvate. For selection of Bcl-2-overexpressing cells, G418 was added to a final concentration of 400 μg/ml. Selection of sh-Bid and sh-scrambled control cells was performed using 2 μg/ml puromycin.

**Reagents and antibodies.** The Smac-164 (SM) was a gift from Prof Pierfausto Seneci (University of Milan, Milan, Italy). Recombinant human interleukin zipper primed TRAIL (iTRAIL), necrostatin-1, HS101 and HS201 mouse monoclonal anti-TRAIL receptor 1 and 2 antibodies were provided by Prof Henning Walczak (University College London, London, UK). The caspase inhibitor z-VAD-fmk (z-VAD) was purchased from Promega (Madison, WI, USA), the human TNF-α ELISA Kit from Life Technologies (Paisley, UK), XIAP siRNA oligonucleotide (5’-AUCCAUCAUGGCAUGUAUA-3’) from MWG Biotechnol- ogy (Ebersberg, Germany), the neutralising IgA monoclonal antibody to human TNF-α from InvivoGen (San Diego, CA, USA) and mouse monoclonal anti-human CD120a (TNF-R1), clone H398 from ABD Serotec (Puchheim, Germany). Antibodies used for immunoblotting were: β-actin (1:10,000), tubulin (1:10,000) (Sigma-Aldrich, St Louis, MO, USA), Bcl-2 (1:1000; Santa Cruz Biotechnology, Dallas, TX, USA), caspase-9 (1:1000), caspase-3 (1:1000), Mcl-1 (1:1000), PARP (1:1000), Bid (1:1000), CoxIV (1:1000) (Cell Signalling, Danvers, MA, USA), caspase-8 (1:500), c-FLIP (1:500) (Enzo Life Sciences, Exeter, UK), cIAP-1 (0.5 μg/ml), R&D System, Minneapolis, MN, USA), cIAP-2 (4 μg/ml), BD Pharmingen, Oxford, UK), Smac/Diablo (1:1000; Epitomics, Burlingame, CA, USA), XIAP (1:4000; BD Transduction Laboratories, Oxford, UK), cytochrome c (1:1000; Abcam, Cambridge, UK) and caspase-10 (1:1000; MBL International, Woburn, MA, USA). Secondary HRP-coupled anti-rabbit (1:2000) and anti-mouse antibodies (1:1000) were obtained from Fisher Scientific (Loughborough, UK) and Sigma-Aldrich, respectively. The p50 and p52 antibodies (1:1000) were provided by Dr Dagmar Kulms, Centre for Regenerative Therapies (Dresden, Germany).

**MTT cell viability assay.** Cells were seeded in 96-well plates at a density of 2–4 × 103 cells one day before SM or TRAIL treatment. In case of the inhibitor studies, 30 μM necrostatin-1 (nec-1) was included in the treatment, whereas z-VAD-fmk (20 μM) was added 1 h in advance. The cells were incubated for 24–72 h (endpoint measurement) or 2–8 h (time kinetic). Twenty microlitres of MTT reagent (5 mg ml−1) and, after 3 h, 150 μl of solubilisation solution (50% dimethylformamide, 0.2% glacial acetic acid, 20 mM HCl, 10% SDS) was added to each well. After 16–24 h, OD595 was measured using the LT-400 microplate reader (Labtech, Uckfield, East Sussex, UK). The statistical analysis of the results was performed using Student’s unpaired two-tailed t-test (GraphPad Prism 5 software, La Jolla, CA, USA).

**Immunoblot analysis.** Cells were trypsinised, washed in 1 × PBS and then resuspended in lysis buffer (1 mM MgCl2, 12.5 mM HEPES/KOH, pH 7.4, 1 mM EGTA, 0.1% Triton X-100) including protease inhibitors. After 30 min incubation on ice, the protein lysates were obtained by centrifugation (13 200 r.p.m. for 15 min at 4°C) and the protein concentration was determined by the Bradford assay (Bradford, 1976). Thirty micrograms of protein was separated on 10–15% 1.5-mm-thick SDS gels, then transferred to nitrocellulose membranes (400 mA for 90 min) and subsequently
probed with the respective antibodies. The Mini-PROTEAN electrophoresis system combined with the Mini-Trans Blot module (Bio-Rad, Hercules, CA, USA) was used for protein electrophoresis and tank transfer.

**Lentiviral knockdown.** Lentiviral constructs were produced in HEK 293T cells. HEK 293T cells were transfected with the construct of interest as well as plasmids coding for gag/pol and env using calcium phosphate as described previously (Jordan and Wurm, 2004). At 24, 36 and 48 h after transfection, viral supernatants were harvested and filtered through a 0.45 μm filter. For the storage of the virus at -80 °C, 5 μg ml⁻¹ polybrene was added. Infection of target cells with virus was performed overnight. Cells were selected depending on their newly acquired antibiotic resistance. A control of nontransduced cells was treated in parallel to ensure toxicity of the antibiotic. The pGIPZ-sh-Bid constructs including the sh-scrambled control were kindly provided by Prof. Pascal Meier (the Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK). A mixture of five Bid sh-RNAs was used for transduction. The lentiviral, doxycycline-inducible TRIPZ caspase-8 and scrambled control sh-RNAs were a gift from Prof. Meier (San Jose, CA, USA).

**Response of HNSCC to TRAIL and Smac mimetics.** To assess the therapeutic potential of TRAIL and Smac mimetics for clinical application, we treated HNSCC cell lines with TRAIL or Smac mimetics (et al, 2007). Briefly, cells of four confluent 15 cm plates were harvested for each condition, cells were washed twice with 1 × PBS and resuspended 1 : 1 in ice-cold IB, buffer (10 mM Tris, pH 7.5, 1 mM EGTA, 200 mM sucrose, plus protease inhibitor cocktail). After 30 min, incubation cells were lysed using a 26 G syringe until ~60% of the cells were Trypan blue positive. Several centrifugation steps were performed at low speed to remove unlysed, intact cells (700–1200 g for 5 min at 4 °C). To obtain a mitochondrial and cytosolic fraction, the supernatant was centrifuged at 7200 g for 20 min (4 °C). The supernatant represented the cytosolic/ER fraction. The pellet (mitochonodria) was washed two times and then lysed in lysis buffer. Thirty micrograms mitochondrial protein was used for immunoblot analysis. Corresponding volumes of the cytosolic fraction were loaded. Purity of each fraction was analysed using specific marker proteins.

**RESULTS**

**Head and neck cancer cell lines show distinct responses to TRAIL and Smac mimetics.** To assess the therapeutic potential of TRAIL and Smac mimetics for clinical application, we treated HNSCC cell lines with TRAIL or Smac mimetics. Head and neck cancer cell lines show distinct responses to TRAIL or Smac mimetics. In the responsive HNSCC cell lines, the supernatant was centrifuged at 7200 g for 20 min (4 °C). The supernatant represented the cytosolic/ER fraction. The pellet (mitochonodria) was washed two times and then lysed in lysis buffer. Thirty micrograms mitochondrial protein was used for immunoblot analysis. Corresponding volumes of the cytosolic fraction were loaded. Purity of each fraction was analysed using specific marker proteins.
HNSCC cell lines with evidence of partial RIPK1-dependent necroptotic cell death in response to SM.

**Distinct protein signature predicts TRAIL and SM sensitivity.** The differential responses to TRAIL or SM among the HNSCC cell lines provided an ideal model to identify a predictive gene expression signature for tumour cell susceptibility to these drugs. Evaluation of several protein markers involved in cell death pathways indicated clear differences between several proteins: caspase-8 level was significantly higher in TRAIL-sensitive cell lines, and also increased expression levels of c-FLIP, cIAP-2 and XIAP, cIAP-1, Mcl-1, Smac/DIABLO and caspase-3 protein was observed only in TRAIL-sensitive H357 cells. Cleavage occurred as early as 2 h after TRAIL treatment. The presence of cleaved PARP protein, indicative of caspase-3 activity, was detected in sensitive H357 cells (Figures 2E and F), suggesting a type II extrinsic apoptosis mechanism involving Bid, Bcl-2 and PARP cleavage.

**TRAIL induces type II extrinsic apoptosis in responsive HNSCC cells.** To characterise the apoptotic pathway induced by TRAIL in responsive HNSCC cell lines, the kinetics of caspase activation were analysed in representative TRAIL-responsive (H357) and resistant (HSC3) cell lines. Cleavage of caspase-8 into the active p18 fragment and caspase-3 into the active p17 fragment were observed only in TRAIL-sensitive H357 cells. Cleavage occurred as early as 2 h after TRAIL treatment. The presence of cleaved PARP protein, indicative of caspase-3 activity, was detected in H357 cells only. Additionally, cleavage of the full-length Bid protein to generate tBid was observed in conjunction with caspase-8 activation at an early stage of apoptosis in H357 cells, indicating a role for Bid in mediating TRAIL-induced cell death (Figure 2A).

To determine the importance of Bid in TRAIL-induced death, H357 and HSC3 Bid knockdown and control cells were generated (Figure 2B) and analysed for response to TRAIL. Over 30% increased cell survival was observed in Bid-knockdown H357 cells as compared with sh-scrambled control after treatment with 100 ng ml⁻¹ TRAIL (Figure 2C). In addition, cleavage and activation of caspase-9 correlated with cell type-specific sensitivity (Figure 2D) and further supported a mitochondrial involvement during TRAIL-induced apoptosis in HNSCC cell lines. Additionally, Bcl-2 overexpression resulted in increased resistance to TRAIL in sensitive H357 cells (Figures 2E and F), suggesting a type II extrinsic apoptosis mechanism involving Bid, Bcl-2 and mitochondria.

IAP family members such as XIAP have been implicated in cell death in response to TRAIL treatment (Lu et al, 2008;
Ndozangue-Touriguine et al., 2008; Allensworth et al., 2012). We investigated cIAP-1 and XIAP protein levels in TRAIL-sensitive UMSCC11B cells following 2 to 12 h of TRAIL treatment. Both proteins showed reduced levels with increasing duration of TRAIL treatment (Figure 2G). However, XIAP downregulation was caspase-mediated as it was blocked by z-VAD (Figure 2H). Additionally, downregulation of XIAP by siRNA neither had an additional sensitisation effect of TRAIL-responsive cells to TRAIL.
Smac mimetics induce cell death in HNSCC cells through caspase-10 activation. To examine the importance of caspase-8 in response to SM, doxycycline-inducible caspase-8 knockdown

Figure 3. Smac mimetic-induced cell death is mainly caspase-8 independent and associated with cytochrome c release. (A) HSC cells were either infected with an inducible lentiviral sh-caspase-8 or a scrambled (scr) sh-RNA control. Expression of the sh-RNA was induced by addition of 1 μg/ml doxycycline for 36 h. The efficiency of the caspase-8 knockdown in HSC3 cells was determined by immunoblotting. Non-induced cells served as control. (B) Induced HSC3 caspase-8 knockdown or sh-scr control cells were treated with increasing concentrations of SM. Cell viability was analysed 24 h later by MTT assay. Values indicate means ± s.d. of three independent experiments (n = 3). (C) Immunoblotting for full-length and cleaved caspase-10 and -3 in response to treatment with 200 nM SM for up to 6 h. Caspase-10 fragments that were specifically detected in SM-sensitive HSC3 cells are marked. (D) HSC3 and H357 cells were incubated with 200 nM SM for 3 h. Cytochrome c release was analysed by subcellular fractionation. Purity of each fraction was assessed using characteristic marker proteins. Thirty micrograms of mitochondrial fractions were loaded. (E) Cleavage of caspase-9 was analysed in response to 3 h of 200 nM SM treatment in representative sensitive (HSC3) and resistant (H357) cell lines. (F) HSC3M3 cells were treated with 50 nM SM. After 2, 4, 8 and 12 h capase-3 activation, PARP cleavage, cIAP-1 and XIAP protein levels were analysed. (G) Treatment of HSC3M3 with 50 ng/ml TRAIL or 50 nM SM ± the pancaspase inhibitor z-VAD-fmk (20 μM). After 8 h of treatment, cIAP-1 and XIAP protein levels were analysed by immunoblotting. (H) Transient knockdown of XIAP in HSC3M3 cells. Cell viability in response to 50 ng/ml TRAIL or 50 nM SM was analysed after 24 h by MTT assay. Values are shown as means ± s.d. of three independent experiments (n = 3). Efficient knockdown was confirmed by immunoblotting.
HSC3 cells were generated and tested for sensitivity to SM. Depletion of caspase-8 only marginally protected HSC3 cells from SM-induced cell death (Figures 3A and B). We then investigated whether caspase-10 is involved in SM-induced cell death and showed cleavage and activation of caspase-10 in response to SM treatment (Figure 3C). Similar levels of caspase-10 cleavage and activation were observed in caspase-8 knockdown compared with sh-scrambled control HSC3 cells in response to SM treatment (Figure 3A and Supplementary Figure S4A), indicating a caspase-8-independent mechanism of caspase-10 activation. These results suggest that caspase-10 may substitute for the lack of caspase-8 or cooperate with low caspase-8 activity to induce cell death in response to SM. Importantly, there was no cleavage of caspase-10 in response to SM or TRAIL treatment in TRAIL-sensitive (SM-resistant) H357 cell line (Figure 3C and Supplementary Figure S4B).

We then examined the mechanism of cell death downstream of initiator caspases and observed cytochrome c release, as well as cleavage and activation of caspase-9 at 3 h after SM treatment. This result suggests a role for the intrinsic mitochondrial apoptosis pathway in sensitivity of cells to SM (Figures 3D and E). As a role for caspase-10 in Bid cleavage has been previously reported (Fischer et al., 2006), we investigated whether caspase-10 activation led to mitochondrial dysfunction via proapoptotic Bid protein. SM treatment reduced full-length Bid protein in sensitive HSC3 cells (Supplementary Figure S5A). Furthermore, Bid knockdown (Figure 2B) diminished the level of cytochrome c release in response to SM treatment (Supplementary Figure S5B). However, Bid knockdown did not inhibit the effect of SM in the sensitive HSC3 cells (Supplementary Figure S5C), suggesting a Bid-independent caspase-10-mediated cell death by SM.

Further we investigated the role of IAPs in SM sensitivity of HNSCC cells (Figure 3F). Smac mimetic induced cell death as evident by caspase-3 activation in the responsive cells as early as 4 h after treatment and also resulted in early cIAP-1 depletion and downregulation of XIAP. Downregulation of XIAP but not XIAP was caspase-mediated as the effect was blocked by the addition of z-VAD (Figure 3G). These data suggest that XIAP does not have a decisive role in SM-induced apoptosis in HNSCC. In agreement with these data, XIAP knockdown did not significantly increase sensitivity of responsive cells to SM (Figure 3H). Importantly, XIAP knockdown also did not sensitize SM-resistant cells to SM, indicating different processes other than XIAP being responsible for SM resistance (Figure 2I). By contrast, depletion of cIAP-1 occurred in both sensitive and resistance cell lines after SM treatment, implying that the observed distinct SM response in HNSCC cell lines was not solely mediated by cIAP-1.

TNF-α levels determine SM sensitivity. IAP antagonists are known to induce NF-κB-mediated production of TNF-α resulting in killing of the cells through an autocrine mechanism (Vince et al., 2007). We therefore investigated the expression of endogenous TNF-α and its induction in response to SM and TRAIL in HNSCC cell lines. A direct correlation between TNF-α secretion levels and SM sensitivity in HNSCC cell lines was detected. Non-stimulated SM-sensitive HSC3 and HSC3M3 cells showed significantly higher levels of secreted TNF-α than resistant HN30, UMSCC11B and H357 cells (Figure 4A). Smac mimetics further induced autocrine TNF-α secretion by up to six-fold over endogenous levels in SM-sensitive but not -resistant cell lines. TRAIL treatment had no significant effect on TNF-α secretion in all cell lines tested. Importantly, addition of TNF-α-blocking antibody rescued SM-sensitive HSC3 cells from SM-induced cell death (Figure 4B) and combining SM with rhTNF-α sensitised resistant UMSCC11B cells to SM inducing 60% cell death (Figures 4C and D). These data show a decisive role for autocrine TNF-α secretion in SM-mediated cell death in HNSCC cell lines.

The difference in TNF-α secretion levels between SM-sensitive and -resistant cell lines was concomitant with the activity of the noncanonical NF-κB signalling pathway (Figure 4E). The SM-sensitive HSC3 cells demonstrated baseline level of p100 processing and p52 generation before treatment, which was further increased in response to SM. This effect was observed at early time points, suggesting a role for p100 processing in the initiation stages of cell death and coincided with a clear caspase-3 cleavage and activation (Supplementary Figure S5A). By contrast, SM-resistant H357 cells lacked baseline p100 processing and did not generate p52 in response to SM treatment.

Collectively, our data indicate a cell line-specific response to the cytotoxic effect of TRAIL and SM in HNSCC. The pathways used, such as type I or II extrinsic apoptosis and/or necroptosis, are determined by the cellular levels of the proapoptotic proteins such as caspase-8, Bid and TNF-α. Our results also identify caspase-10 as an important initiator caspase in response to SM in cell lines with low endogenous caspase-8 activity.

**DISCUSSION**

Treatment modalities for head and neck cancers remain to be surgery and radiotherapy alone or in combination with chemotherapy. These treatment modalities are ineffective in most patients and are associated with severe side effects. Currently, no effective targeted drugs are available for this type of cancer. Targeted agents, however, such as TRAIL and SMs have been reported to kill tumour cells while sparing non-immortalised cells (Walczak et al., 1999; Müller-Sienerth et al., 2011). Additionally, TRAIL and SMs have shown promising anticancer activity in phase I and phase II clinical trials for certain types of advanced cancers (Lu et al., 2008; Cai et al., 2011; Mahalingam et al., 2011; Gasparini et al., 2013). We therefore investigated their potential as anticancer drugs for head and neck cancers by testing their effect in a panel of HNSCC cell lines. We then sought to identify biomarkers that could predict the response to TRAIL and SM treatment.

Smac mimetics have been reported to sensitize HNSCC cells to radiotherapy, chemotherapy or TRAIL treatment (Ren et al., 2007; Sun et al., 2011; Xu et al., 2011; Yang et al., 2011), but could not induce cell death as a single agent in HNSCC cell lines such as 1483 and JHU-6012 (Sun et al., 2011). Here we show that izTRAIL and Smac-164 (SM) effectively kill specific HNSCC cell lines as single agents when used at very low concentrations. Uniquely, the HNSCC cell lines in the panel were either sensitive to TRAIL or SM with no cell line being clearly sensitive to both agents. This selective response led to the investigation of the molecular pathways involved in response to each drug as such knowledge could help in the future stratification of patients for suitable treatment option.

Protein expression analysis identified caspase-8 as an important biomarker for TRAIL sensitivity as well as an indicator of the type of apoptotic pathway involved. TRAIL-resistant HNSCC cells are characterised by almost undetectable levels of caspase-8, whereas TRAIL-sensitive cells express either high or moderate levels and use the type I and type II extrinsic apoptotic pathway, respectively. Caspase-8 protein levels have been associated with survival and prognosis of different solid and haematological malignancies (Pingoud-Meier et al., 2003). Upregulation of caspase-8 has been shown to sensitize acute lymphoblastic leukaemia cells to chemotherapeutic drugs, whereas low caspase-8 levels were associated with poor prognosis.

Recently, procaspase-8 mutations have been identified in HNSCC primary tumour samples as well as in HNSCC cell lines (Agrawal et al., 2011; Stransky et al., 2011; Pickering et al., 2013). Importantly, heterozygous procaspase-8 mutations have been
were incubated in the presence of increasing concentrations of rhTNF-α combination with 200 µg/ml blocking antibody (ab) for 4 h. Cell viability was measured by MTT assay. Values are means ± s.d. of three independent experiments (n = 3). (B) HSC3 cells were treated with 50 nM SM alone or in combination with 200 µg/ml–1 TNF-α blocking antibody (ab) for 4 h. Cell viability was measured by MTT assay. Values are means ± s.d. of three independent experiments (n = 3). (C) Cell viability of HSC3M3 and UMSCC11B cells was determined by MTT assay after 24 h treatment with 10 ng/ml–1 rhTNF-α, 50 nM SM or 50 ng/ml–1 TRAIL. Values indicate means ± s.d. of three independent experiments (n = 3). (D) UMSCC11B cells were incubated in the presence of increasing concentrations of rhTNF-α alone or combined with 50 ng/ml–1 TRAIL or 50 nM SM. Cell viability was measured 24 h later by MTT assay. Values are means ± s.d. of three independent experiments (n = 3). (E) The effect of 200 nM SM on the noncanonical NF-κB signalling pathway was analysed in SM-sensitive HSC3 and -resistant H357 cells. Processing of p100 to p52 was assessed by immunoblotting.

Figure 4. TNF-α levels correlate with SM sensitivity and partially resistant HNSCC cells to SM. (A) Three SM-sensitive cell lines (HSC3, HSC3M3 and HN5) and three SM-resistant cell lines (HN30, UMSCC11B and H357) were treated with 50 ng/ml–1 TRAIL or 50 nM SM for 24 h. The amount of secreted TNF-α was determined using ELISA. The experiment was performed in duplicate; the results depicted are the average of the TNF-α concentration in the tested samples. One of two independent experiments is shown. (B) HSC3 cells were treated with 50 nM SM alone or in combination with 200 µg/ml–1 TNF-α blocking antibody (ab) for 4 h. Cell viability was measured by MTT assay. Values are means ± s.d. of three independent experiments (n = 3). (C) Cell viability of HSC3M3 and UMSCC11B cells was determined by MTT assay after 24 h treatment with 10 ng/ml–1 rhTNF-α, 50 nM SM or 50 ng/ml–1 TRAIL. Values indicate means ± s.d. of three independent experiments (n = 3). (D) UMSCC11B cells were incubated in the presence of increasing concentrations of rhTNF-α alone or combined with 50 ng/ml–1 TRAIL or 50 nM SM. Cell viability was measured 24 h later by MTT assay. Values are means ± s.d. of three independent experiments (n = 3). (E) The effect of 200 nM SM on the noncanonical NF-κB signalling pathway was analysed in SM-sensitive HSC3 and -resistant H357 cells. Processing of p100 to p52 was assessed by immunoblotting.

described for HN30, HN5 (Pickering et al, 2013) and HSC3 cells, which have been used in this study (Catalogue of Somatic Mutations in Cancer, COSMIC, Cell Lines Project). As these cell lines differ in their sensitivity to TRAIL treatment, pro-caspase-8 mutagenesis analyses do not seem to be a useful tool to predict TRAIL sensitivity. Instead, measuring caspase-8 protein levels might be a more useful biomarker of predicting treatment response. However, in head and neck cancers further investigations are needed to determine the differences in caspase-8 protein levels and its association with clinical outcome.

Analysis of the mechanism of SM-induced cell death in HNSCC cells demonstrated that RIPK1-dependent necroptosis may have a role in SM sensitivity in certain HNSCC cell lines as treatment with nec-1 increased cell survival by a small but significant amount (Figure 1C). Cell death induced by SMs has been shown to be dependent on caspase-8 but not caspase-9 activity (Petersen et al, 2007). In this HNSCC cell line panel, SM sensitivity was demonstrated to be caspase-8 independent as its knockdown had minor effect on response to SMs. Interestingly, caspase-10 was shown to become activated as detected by its cleavage in response to SM, suggesting that in the absence or low caspase-8 levels, caspase-10 may substitute and initiate the apoptotic signalling by SM, suggesting that in the absence or low caspase-8 levels, caspase-10 may substitute and initiate the apoptotic signalling by SM. As described above, caspase-9 activity has shown not to be required for SM-induced cell death, thus the importance of the intrinsic pathway in SM-induced cell death in HNSCC remains to be elucidated.

Overexpression of XIAP has been associated with TRAIL resistance in different tumour types (Gillissen et al, 2013). Additionally, combined XIAP and cIAP-1 knockdown was shown to increase the sensitivity of prostate cancer cells to TRAIL treatment (Dai et al, 2009). In TRAIL-resistant HNSCC cells depletion of XIAP did not affect the response to TRAIL, suggesting that XIAP is not important in conferring resistance to TRAIL. As TRAIL treatment induced both cIAP-1 and XIAP downregulation in TRAIL-sensitive HNSCC cells, it is conceivable that inhibition of both cIAP-1 and XIAP is required to sensitize resistant HNSCC cells to TRAIL, and this needs further investigation.

TNF-α has been proposed as the main culprit in cancer cell apoptosis induced by SMs (Petersen et al, 2007; Varfolomeev et al, 2007; Vincze et al, 2007). Notably, the basal levels of TNF-α secretion
were much higher in SM-sensitive HNSCC cells than in -resistant cell lines. Smac mimetics treatment further increased the levels of secreted TNF-α in responsive HNSCC cell lines but not in the resistant ones. TNF-α serum levels might thus be a predictive marker for SM sensitivity in head and neck cancer. TNF-α serum levels are widely used indicators for the efficiency of different treatment strategies and outcome of disease in diverse cancer types (Kurokawa et al, 1998; D'Silva and Ward, 2007; Su et al, 2011; Wang et al, 2013; Tripsanis et al, 2014), their analysis is therefore already established and could provide a noninvasive future strategy to predict SM or TRAIL treatment response in head and neck cancer.

Upregulation of TNF-α in response to SM treatment has previously been reported to induce TNF-α-dependent cell death in responsive cell lines. However, TNF-α-independent cell death is also possible in this setting (Allensworth et al, 2013). In this study, the addition of TNF-α alone to SM-sensitive HNSCC cell lines resulted in apoptosis but at a significantly lower level as compared with SM alone treatment, indicating that TNF-α upregulation by itself is insufficient to initiate SM-dependent response in HNSCC cells; cIAP protein downregulation (e.g. by SM) is additionally required supporting the notion of a ‘dual-hit’ mechanism. Importantly, SM-resistant cells already show a decrease in cIAP-1 protein expression in the presence of SM (Figure 2G) and can then be sensitised to SM-induced cell death by the addition of TNF-α.

Smac mimetics target cIAPs in particular cIAP-1 to stimulate their autoubiquitination and degradation, which results in the activation of NF-κB and TNF-α secretion and consequently activation of caspase-8 and cell death. Here we demonstrated that SM-sensitive cell lines have an active noncanonical NF-κB signalling pathway in the absence of cellular stress, this was further induced by treatment with SM corresponding to increased TNF-α secretion. In conclusion, this study shows that TRAIL and Smac-164 are highly effective in killing all HNSCC cell lines tested and have important potential as future targeted treatments of head and neck cancers. Caspase-8 expression was identified as a biomarker for predicting TRAIL sensitivity, whereas high TNF-α level corresponded with SM sensitivity with TNF-α being able to sensitise SM-resistant cells to SMs. Interestingly, caspase-10 was found to contribute to SM-induced cell death in the absence of caspase-8. Further investigations including other HNSCC cell lines as well as in vivo studies will determine the future application of TRAIL and SMs as novel therapeutics for HNSCC patients.

ACKNOWLEDGEMENTS

We thank Professors Pascal Meier, the Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK, for TRIPZ-inducible lentiviral sh-caspase-8 and Simone Fulda, JW Goethe University Hospital Frankfurt, Germany for pGIPZ-shBID. We also thank Sebastian Kupka, UCL Cancer Institute, London, UK for helpful discussions. Nina Raulf was supported by a scholarship from the Egyptian government, Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, El-Attar was supported by a research grant from the Rosetrees Trust and Radien Institute, London, UK for helpful discussions. Nina Raulf was for pGIPZ-shBid. We also thank Sebastian Kupka, UCL Cancer Institute, London, UK, for TRIPZ-inducible lentiviral sh-caspase-8 and Breast Cancer Research Centre, Institute of Cancer Research, London, UK, for TRIPZ-inducible lentiviral sh-caspase-8.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Falckry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevino L, Drummond JA, Muzany DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333(6046): 1154–1157.

Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR (2012) XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Mol Cancer Therap 11(7): 1518–1527.

Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR (2013) Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism. Breast Cancer Res Treat 137(2): 359–371.

Bockbrader KM, Tan M, Sun Y (2005) A small molecule Smac-mimetic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 24(49): 7381–7388.

Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.

Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu, Qiu S, Yang CY, Miller R, Yi H, Zhang T, Sun D, Kang S, Guo M, Leopold L, Yang D, Wang S (2011) A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 54(8): 2714–2726.

Chen DJ, Huerta S (2009) Smac mimetics as new cancer therapeutics. Anti-Cancer Drugs 20(8): 646–658.

Creagh EM, Murphy BM, Duriez PJ, Duckett CS, Martin SJ (2004) Smac/Diablo antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins. Nat Biol Chem 279(26): 26906–26914.

D'Silva NJ, Ward BB (2007) Tissue biomarkers for diagnosis & management of oral squamous cell carcinoma. AlphaOmega 100(4): 182–189.

Dai Y, Liu M, Tang W, Li Y, Lian J, Lawrence TS, Xu L (2009) A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer 9: 392.

Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997) XIAP is a direct inhibitor of cell-death proteases. Nature 388(6639): 300–304.

Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytoschrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102(1): 33–42.

Falschlechner G, Ganten TM, Koschyn R, Schaefer U, Walczak H (2009) TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 647: 195–206.

Fischer U, Strehl, C, Schulze-Osthoff K (2006) Unique and overlapping substrate specificities of caspase-8 and caspase-10. Oncogene 25(1): 152–159.

Frezza C, Cipolat S, Scorrano L (2007) Organelle isolation: fundamental mitochondria from mouse liver, muscle and cultured fibroblasts. Nat Protocols 2(2): 287–295.

Gasparini C, Vecchi Brumatti L, Monasta L, Zauli G (2013) TRAIL-based therapeutic approaches for the treatment of pediatric malignancies. Curr Med Chem 20(17): 2254–2271.

Gillissen B, Richter A, Richter A, Overkamp T, Essmann F, Hemmati PG, Preisser R, Belka C, Daniel PT (2013) Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type F’ mode. Cell Death Dis 4: e643.

Herbst RS, Eckhardt SG, Ebbinghaus S, O’Dwyer PJ, Gordon MS, Herbst RS, Eckhardt SG, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR, Herbst RS, Eckhardt SG, Jordan M, Wurm F (2004) Transfection of adherent and suspended cells by calcium phosphate. Adv Exp Med Biol 575: 136–143.

Juo P, Wio MS, Kuo CJ, Signorelli P, Biemann HP, Hannun YA, Blenis J (1999) FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ 10(12): 797–804.

Kantari C, Walczak H (2011) Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta 1813(4): 558–563.

Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, Gazar D, Avvisati B (2003) Death receptor recruitment of procaspase-8 by Smac mimetics sensitizes prostate cancer cells to TRAIL-induced apoptosis. J Biol Chem 278(32): 30226–30233.
